

Vaccine Updates for 2023: RSV and More

USHP Fall Resident CE Series – 11/09/2023

Advisory Committee on Immunization Practice (ACIP)

- Provide vaccine recommendations to the CDC
- Most up-to-date info found online at ACIP Recent Meeting Recommendations

Respiratory Syncytial Virus (RSV)

Adults ≥ 60 years old may receive an RSV vaccine using shared clinical decision-making

- A single dose of either RSVpreF (Abrysvo™) or RSVpreF3 (Arexvy™)
- Vaccination should be offered as soon as available
- Delay vaccination for moderate-severe acute illness
- Can be administered with other vaccines – may increase reactogenicity effects if RSVpreF3 is administered with other adjuvanted vaccines
- Most efficacious in adults >65 years old and in patients with chronic diseases

Maternal Respiratory Syncytial Virus (RSV) vaccine is recommended for pregnant people during 32 through 36 weeks gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants.

- Only RSVpreF (Abrysvo™) can be used
- Seasonal administration will typically be between Sept-Jan the US
- Time to maternal antibody transfer is ~14 days
- Nirsevimab may be used as an alternative or adjunct

COVID-19

All patients ≥ 6 months old are recommended to receive an updated mRNA vaccine

Considerations

- Patients with a history of Multisystem Inflammatory Syndrome (MIS)
 - Onset MIS > 60 days vaccination: consider subsequent dose if recovered*
 - Onset MIS ≤ 60 days vaccination: consider patient-specific factors
- Patients with a history of myocarditis or pericarditis
 - Vaccinate if onset was prior to vaccination or onset was >3 weeks after vaccination
 - Generally, avoid vaccination if onset was ≤ 3 weeks from vaccination

Influenza

People with egg-allergy may receive any flu vaccine (egg-based or non-egg based) that is otherwise appropriate for their age and health status

Pneumococcal

Use of either pneumococcal conjugate vaccines (PCV) PCV15 or PCV20 is recommended for all children aged 2–23 months according to currently recommended PCV dosing and schedules.

Mpox

Vaccination with Smallpox/Monkeypox Vaccine, Live, Non-Replicating (Jynneos™) is recommended for patients ≥ 18 years old at risk of mpox during an mpox outbreak

- Complete 2 dose series separated by 4 weeks
- Outbreak is determined by public health authorities
- Pre-exposure or post-exposure prophylaxis is acceptable
- Subcutaneous or intradermal route can be used

Polio

Adults known/suspected to be unvaccinated/incompletely vaccinated -> Vaccinate with IPV 4-dose series

Adults at high risk for poliovirus exposure with completed IPV series -> Consider 1 dose of IPV

References

- Advisory Committee on Immunization Practices (ACIP) | CDC. Accessed September 26, 2023. <https://www.cdc.gov/vaccines/acip/index.html>
- <https://www.cdc.gov/vaccines/acip/acip-scdm-faqs.html>
- ACIP Vaccine Recommendations and Schedules | CDC. Accessed September 26, 2023. <https://www.cdc.gov/vaccines/acip/recommendations.html>
- Fleming-Dutra KE. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Evidence to Recommendations Framework Updates Pfizer Maternal RSVpreF Vaccine Co-lead, Respiratory Syncytial Virus Vaccines-Pediatric/Maternal Work Group Coronavirus and Other Respiratory Viruses Division National Center for Immunization and Respiratory Diseases. Published online 2023.
- Clinical Guidance for COVID-19 Vaccination | CDC. Accessed September 26, 2023. <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#%20covid-vaccines>

Questions?

Abbey Smith, PharmD
PGY2 Ambulatory Care Resident
University of Utah Health
Abbey.smith@hsc.Utah.edu